Lilly's quarterly sales largely offset Cymbalta slide

Drugmaker Eli Lilly and Co's quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for most of its other prescription drugs. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. "Company sales were stronger than thought, but a lot of that upside came from drugs that are already off patent or about to lose patent protection," said Edward Jones analyst Judson Clark. Sales of Cymbalta, which lost U.S. patent protection last month, fell 38 percent to $883 million.



via Health News Headlines - Yahoo News http://ift.tt/1hRGbmb